

OMG...I DIDN'T KNOW THAT!



Adnexal Mass Risk Assessments: Do Algorithms Improve Care?

PODCAST 8

What Is the Lifetime Risk of Developing A Pelvic Mass?





develop a pelvic mass in their lifetime¹



5-10%


will undergo pelvic surgery²





Of those undergoing surgery, 9%-20% will ultimately be diagnosed with a malignancy³

- 1. Mobeen S, Apostol R. Ovarian Cyst. [Updated 2021 Jun 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560541/
- 2. Froyman W, et al. *Diagnostics*. 2017;7(2):32.
- 3. Moore RG, Orr Jr, JW, Sellers JA. Malignancy risk assessment for adnexal ovarian masses. Medscape.org. 2020. https://www.medscape.org/viewarticle/930267

What Is the Lifetime Risk of Developing Ovarian Cancer?







of ovarian cancer is diagnosed **after the age of 55** years (the median age of onset is 63)

Howlader N, Noone AM, Krapcho M, et al (eds). *SEER Cancer Statistics Review, 1975-2016.* National Cancer Institute. https://seer.cancer.gov/csr/1975_2016/. Posted in April 2019. Accessed November 15, 2021.

Initial Ovarian Cancer Symptoms Are Nonspecific and Progress Over Time

While nonspecific symptoms can occur in early disease, the majority of cases of ovarian cancer are diagnosed at a late stage as many individuals only experience symptoms in the presence of widespread metastatic disease.

- Abdominal or back pain
- Bloating
- Feeling full too quickly
- Difficulty eating

- Abnormal vaginal bleeding
- Abnormal vaginal discharge
- Pain or pressure in pelvis
- Frequent or urgent urination
- Constipation

Differential Diagnosis for Ovarian Cancer

Colon cancer **Embryologic remnants** Gastric adenocarcinoma Metastatic gastrointestinal carcinoma **Ovarian** torsion Peritoneal cyst **Retroperitoneal mass** Uterine fibroids Endometriosis Papillary adenocarcinoma Serous adenocarcinomas Undifferentiated adenocarcinomas Small-cell adenocarcinomas Brenner tumors

Arora T, Mullangi S, Lekkala MR. Ovarian Cancer. [Updated 2021 Sep 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567760/

American College of Obstetrics and Gynecology Guidelines for Ultrasounds of Pelvic Masses

- Transvaginal ultrasonography is the recommended imaging for suspected or incidentally identified pelvic mass. No alternative imaging modality has demonstrated sufficient superiority to transvaginal ultrasonography.
- Ultrasound findings that raise the level of concern regarding malignancy include > 10 cm size, papillary or solid components, irregularity, ascites, and high color Doppler flow.
- Transabdominal ultrasonography rather than transvaginal ultrasonography is recommended for young, virginal, or prepubertal adolescents.



Transvaginal ultrasound in a 64-year-old woman with pelvic mass. Surgery revealed an adenocarcinoma of the ovary. Smorgick N, Maymon R. *Int J Womens Health*. 2014;6:857–63.

American College of Obstetrics and Gynecology Guidelines for Surgical Interventions



Simple cysts up to 10 cm in diameter on transvaginal ultrasonography are likely benign and may be safely monitored using repeat imaging without surgical intervention, even in postmenopausal patients.



Minimally invasive procedures are preferred route of surgery for presumed benign adnexal masses. Fertility preservation should be a priority in women who have not completed childbearing.



Serum biomarker panels may be used as an alternative to CA 125 level alone in determining the need for referral to gynecologic oncologist when surgery is required.



Surgical intervention for suspected endometriomas or mature ovarian teratomas is warranted if the masses are large, symptomatic, or growing in size on serial imaging or if malignancy is suspected.

American College of Obstetrics and Gynecology Guidelines for Gynecologic Oncology Referrals

ACOG and the Society of Gynecologic Oncology have developed criteria for referring women with an adnexal mass to a gynecologic oncologist.



Postmenopausal women with elevated CA125 or premenopausal women with very elevated CA125

 And/or findings suggestive of malignancy, ascites, nodular or fixed pelvic mass, or evidence of metastasis



Premenopausal or postmenopausal women with an elevated score on a formal risk assessment test

- Risk of Ovarian Malignancy Algorithm (ROMA)
- Multivariate index assay
- Risk of Malignancy Index (RMI)
- Another U.S.-based scoring system

ROMA Improves Ovarian Cancer Detection and Classifies Risk

	EOC vs. Benign	Premenopausal Women	Early Stages of Malignancy
ROMA	% (95% CI)	% (95% CI)	% (95% CI)
Sensitivity	92.3 (79.1-98.4)	100 (66.4-100)	75 (42.8-94.5)
Specificity	76.0 (68.4-82.6)	74.2 (68.1-79.7)	74.9 (70.3-79.2)
NPV	97.4 (92.7-99.5)	100 (97.9-100)	99.0 (97.0-99.8)

Moore RG, et al. Obstet Gynecol. 2011;118(2, Part 1):280-88.

Role of CA125 and HE4 in Normal and Malignant Ovarian Cancer Cells

CA125


Normal and malignant cells Cell proliferation Tumor growth Metastasis Inhibition of immune response Cell signaling

HE4

Malignant cells Rare benign neoplastic cells Cell proliferation Tumor growth Metastasis Chemoresistance Steroid biosynthesis


Moore RG, Orr Jr, JW, Sellers JA. Malignancy risk assessment for adnexal ovarian masses. Medscape.org. 2020. https://www.medscape.org/viewarticle/930267

Current Standard of Care



Moore RG, Orr Jr, JW, Sellers JA. Malignancy risk assessment for adnexal ovarian masses. Medscape.org. 2020. https://www.medscape.org/viewarticle/930267


Risk of Ovarian Malignancy Assessment (ROMA)



Moore RG, Orr Jr, JW, Sellers JA. Malignancy risk assessment for adnexal ovarian masses. Medscape.org. 2020. https://www.medscape.org/viewarticle/930267

ROMA Calculator App

- The ROMA Calculator app is free to download on the Apple Store.
- Input CA125, HE4, menopausal status, and assay type.
- Patient's ROMA score is calculated for you.





A new casual friendly place where you can find an authentic, audible blend of timely scientific and medical knowledge. Don't miss out!

> FIND US ON YOUR FAVORITE PODCAST CHANNEL